Europe’s pharma industry saw a drop of 27.3% in overall deal activity during Q4 2018, when compared to the last four-quarter average, according to GlobalData’s deals database.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 64 deals worth $3.83bn were announced for the region during Q4 2018, against the four-quarter average of 88 deals.

Of all the deal types, venture financing saw most activity in Q4 2018 with 28, representing a 43.8% share for the region.

In second place was M&A with 22 deals, followed by private equity deals with 14 transactions, respectively capturing a 34.4% and 21.9% share of the overall deal activity for the quarter.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In terms of value of deals, M&A was the leading category in Europe’s pharma industry with $2.14bn, while private equity and venture financing deals totalled $1.09bn and $602.88m, respectively.

Europe pharma industry deals in Q4 2018: Top deals

The top five pharma deals accounted for 77.1% of the overall value during Q4 2018.

The combined value of the top five pharma deals stood at $2.95bn, against the overall value of $3.83bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q4 2018 was Taisho Pharmaceutical Holdings‘ $1.6bn acquisition of Laboratoires UPSA.

In second place was the $692.24m private equity deal with Karo Pharma by EQT VIII and in third place was Covis Pharma’s $371m asset transaction with AstraZeneca.

The $200m private equity deal with Roivant Sciences by NovaQuest Capital Management and RTW Investments and Bristol-Myers Squibb, HBM Healthcare Investments, Maverick Ventures, Merck Ventures, Novo Seeds, OrbiMed Israel Partners, Seventure Partners, Sunstone Capital and Ysios Capital Partners’ venture financing of Galecto Biotech for $90m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.